Hemoglobin Clinical Trials in Seoul
6 recruitingSeoul, South Korea
Showing 1–6 of 6 trials
Recruiting
Danicopan PMS in Korea
Paroxysmal nocturnal hemoglobinuria
AstraZeneca8 enrolled4 locationsNCT07457151
Recruiting
Phase 3
A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment With Pozelimab + Cemdisiran Combination Therapy is and How Well it Works
Paroxysmal nocturnal hemoglobinuria
Regeneron Pharmaceuticals202 enrolled45 locationsNCT05744921
Recruiting
Phase 1Phase 2
A First-in-Human Safety and Efficacy Study of ALN-CFB, a Small Interfering RNA (siRNA) Targeting Complement Factor B, in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria With Persistent Anemia on a C5 Inhibitor
Paroxysmal Nocturnal Hemoglobinuria, PNHPersistent Anemia
Regeneron Pharmaceuticals24 enrolled8 locationsNCT07187401
Recruiting
Phase 3
A Study to Evaluate How Pozelimab + Cemdisiran Combination Therapy Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Whose Current Treatment is Not Working Efficiently
Paroxysmal nocturnal hemoglobinuria
Regeneron Pharmaceuticals35 enrolled19 locationsNCT07154745
Recruiting
A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy
C3 GlomerulopathyParoxysmal nocturnal hemoglobinuria
Novartis Pharmaceuticals21 enrolled3 locationsNCT07416162
Recruiting
Study of Ultomiris® (Ravulizumab) Safety in Pregnancy
PregnancyParoxysmal Nocturnal Hemoglobinuria, PNHUltomiris-exposed Pregnant/ Postpartum+3 more
Alexion Pharmaceuticals, Inc.75 enrolled7 locationsNCT06312644